Americas Hospital Acquired Infection Testing Market (2026 - 2036)

Americas Hospital Acquired Infection Testing Market Analysis and Forecast by Fact.MR

• The Americas hospital acquired infection testing market is estimated at USD 1.09 billion in 2025 and is forecast to expand at a CAGR of 12.8% to reach USD 4.09 billion by 2036.
• The market covers molecular diagnostic tests, immunoassay-based tests, microbiology culture tests, and rapid diagnostic kits used to detect healthcare-associated pathogens including MRSA, C. difficile, S. aureus, and other nosocomial organisms.
• Growth is shaped by increasing regulatory pressure to reduce hospital infection rates, growing adoption of rapid molecular diagnostic platforms, expanding infection prevention budgets, and rising demand for faster pathogen identification across hospital and laboratory settings.

Summary of Americas Hospital Acquired Infection Testing Market

• Market Snapshot
  • In 2025, the global Americas Hospital Acquired Infection Testing Market was valued at approximately USD 1.09 billion.
  • The market is estimated to reach USD 1.23 billion in 2026 and is projected to attain USD 4.09 billion by 2036.
  • The americas hospital acquired infection testing market is likely to expand at a CAGR of 12.8% during the forecast period.
  • The market is anticipated to create an absolute dollar opportunity of USD 2.86 billion between 2026 and 2036.
  • MRSA Testing Kits accounts for 22.7% of test share in 2026.
  • USA (17.3%) and Brazil (16.0%) are the key growth markets during the forecast period.
• Demand and Growth Drivers
  • Increasing regulatory pressure on healthcare facilities to reduce hospital acquired infection rates is driving investment in diagnostic testing capabilities and infection surveillance programmes.
  • Growing adoption of rapid molecular diagnostic platforms that deliver pathogen identification in hours rather than days is shifting testing from culture-based methods toward PCR and nucleic acid-based approaches.
  • Expanding hospital infection prevention budgets are supporting broader testing protocols, including active surveillance testing for MRSA, C. difficile, and other high-priority organisms.
  • Rising healthcare-associated infection awareness following the post-pandemic emphasis on infection control is sustaining institutional investment in diagnostic infrastructure.
  • Hospital accreditation requirements linking infection rate reporting to quality metrics and reimbursement are creating mandatory testing demand.
• Product and Segment View
  • MRSA Testing Kits accounts for 22.7% of the test segment in 2026, supported by strong adoption and established demand.
  • Hospitals represents 48.9% of the end use segment in 2026, with demand shaped by core market drivers.
  • Blood Samples accounts for 33.7% of the sample type segment in 2026.
• Key segmentation includes:
  • By Test: MRSA Testing Kits, Staphylococcus aureus Detection Kits, Clostridium difficile Testing Kits, Helicobacter pylori Testing Kits, Rotavirus/Adenovirus PCR Kits, Calprotectin Test Kits
  • By Product: Molecular Diagnostic Tests, Immunoassay Based Tests, Microbiology Culture Tests, Rapid Diagnostic Tests, Consumables and Reagents
  • By Application: Bloodstream Infections, Urinary Tract Infections, Surgical Site Infections, Respiratory Infections, Gastrointestinal Infections
  • By End Use: Hospitals, Diagnostic Laboratories, Academic and Research Institutes
  • By Sample Type: Blood Samples, Urine Samples, Respiratory Samples, Wound Samples, Stool Samples
• Geography and Competitive Outlook
  • North America is a leading regional market supported by established clinical infrastructure and strong product adoption.
  • Europe maintains steady demand shaped by clinical standards and mature distribution channels.
  • Asia Pacific is the fastest-growing region, with USA and Brazil leading through rising demand and expanding infrastructure.
  • USA (17.3%) and Brazil (16.0%) are the fastest-growing country markets during the forecast period.
  • Key companies include Thermo Fisher Scientific, bioMerieux SA, Becton Dickinson & Co., Abbott, Danaher, and others.
• Analyst Opinion
  • Shambhu Nath Jha, Principal Consultant at Fact.MR, says 'The Americas HAI testing market is entering an acceleration phase driven by the convergence of regulatory mandates, clinical evidence linking rapid diagnosis to reduced transmission, and the commercial maturity of molecular diagnostic platforms. The USA dominates regional demand, but Latin American markets are growing faster from a lower base as hospital accreditation standards tighten and infection prevention becomes a regulatory requirement. The competitive landscape favours companies with integrated diagnostic platforms that combine rapid molecular testing with antimicrobial susceptibility profiling, enabling clinicians to select targeted therapy within hours rather than days.'

Key Growth Drivers, Constraints, and Opportunities

Key Factors Driving Growth

• Increasing regulatory pressure on healthcare facilities to reduce hospital acquired infection rates is driving investment in diagnostic testing capabilities and infection surveillance programmes.
• Growing adoption of rapid molecular diagnostic platforms that deliver pathogen identification in hours rather than days is shifting testing from culture-based methods toward PCR and nucleic acid-based approaches.
• Expanding hospital infection prevention budgets are supporting broader testing protocols, including active surveillance testing for MRSA, C. difficile, and other high-priority organisms.

Key Market Constraints

• High per-test costs for molecular diagnostic platforms limit adoption in budget-constrained hospital settings, particularly in Latin American markets.
• Technical complexity of molecular diagnostic systems requires trained laboratory personnel and infrastructure that may not be available in smaller facilities.
• Reimbursement limitations for surveillance testing in some healthcare systems constrain the expansion of active screening programmes beyond clinical indication-based testing.

Key Opportunity Areas

• Development of point-of-care rapid diagnostic tests that deliver results at the bedside without laboratory infrastructure creates new testing demand outside centralized laboratories.
• Expansion of antimicrobial stewardship programmes that link rapid pathogen identification with targeted antibiotic prescribing creates clinical demand for integrated diagnostic solutions.
• Growth of hospital infection prevention requirements across Latin American healthcare systems creates new institutional demand for HAI testing infrastructure.

Segment-wise Analysis of the Americas Hospital Acquired Infection Testing Market

• MRSA Testing Kits holds 22.7% of the test segment in 2026.
• Hospitals represents 48.9% of the end use segment in 2026.
• Molecular Diagnostic Tests holds 31.8% of the product segment.

The americas hospital acquired infection testing market is segmented by test, product, end use, sample type, and region. MRSA Testing Kits leads the test segment by value, while molecular diagnostic tests leads the product segment.

Which Test Segment Leads the Americas Hospital Acquired Infection Testing Market?

MRSA testing kits are expected to account for 22.7% of the test segment in 2026. This position reflects the clinical priority placed on MRSA screening and surveillance across hospital settings, driven by the high morbidity and mortality associated with methicillin-resistant Staphylococcus aureus infections. Active surveillance testing for MRSA colonization is mandated or recommended by infection control guidelines in many healthcare systems.

C. difficile testing kits, S. aureus detection kits, and H. pylori testing kits represent additional significant test categories. The test mix reflects the relative clinical priority and regulatory mandate strength for each pathogen across the Americas region.

Which Product Segment Dominates the Americas Hospital Acquired Infection Testing Market?

Molecular diagnostic tests are expected to account for 31.8% of the product segment in 2026. This leadership reflects the shift from traditional culture-based methods toward PCR and nucleic acid amplification technologies that provide faster and more sensitive pathogen detection. Molecular platforms are becoming the standard of care for critical pathogens where rapid identification affects clinical decision-making.

Immunoassay-based tests and rapid diagnostic tests serve point-of-care and screening applications. Microbiology culture tests remain relevant for antimicrobial susceptibility testing and confirmatory diagnosis. The product mix is shifting toward molecular diagnostics as platform costs decrease and clinical evidence strengthens.

Which End Use Segment Dominates the Americas Hospital Acquired Infection Testing Market?

Hospitals are expected to hold 48.9% of the end use segment in 2026. This concentration reflects the hospital setting as the primary site of healthcare-associated infection occurrence and the primary target of infection prevention and surveillance programmes.

Diagnostic laboratories, including reference laboratories that process hospital samples, represent the second major end use segment. Academic and research institutes contribute to testing demand through clinical research, surveillance studies, and antimicrobial resistance monitoring programmes.

Which Product Trend is Shaping the Next Phase of Growth in the Americas Hospital Acquired Infection Testing Market?

Multiplex molecular diagnostic panels that test for multiple pathogens simultaneously are the most significant product development trend. These platforms enable clinicians to identify the causative pathogen and relevant resistance markers from a single sample in under two hours, compared to 48 to 72 hours for traditional culture methods. Syndromic panel testing for bloodstream, respiratory, and gastrointestinal infection panels is gaining rapid clinical adoption.

The multiplex trend reflects a broader clinical demand for actionable diagnostic information that supports antimicrobial stewardship. By providing rapid, comprehensive pathogen and resistance data, these panels enable targeted antibiotic prescribing, reduce unnecessary broad-spectrum antibiotic use, and support hospital infection control interventions. Companies that combine broad pathogen coverage with antimicrobial resistance profiling in a single rapid test are gaining significant competitive advantage in hospital laboratory procurement.

Regional Outlook Across Key Markets

• The USA leads growth at 17.3%, supported by strong regulatory mandates, established infection prevention programmes, and broad adoption of molecular diagnostic platforms across hospital networks.
• Brazil follows at 16.0%, with growth shaped by expanding hospital accreditation requirements, growing infection prevention investment, and increasing availability of molecular diagnostic infrastructure.
• Mexico at 14.7% reflects rising healthcare facility standards, growing awareness of HAI impact, and expanding laboratory diagnostic capacity across hospital systems.

CAGR Table

Source: Fact MR (FMR) analysis, based on proprietary forecasting model and primary research.

Market Outlook for HAI Testing in the United States

The USA hospital acquired infection testing market is projected to grow at a CAGR of 17.3% through 2036. Demand is driven by strong regulatory mandates, established infection prevention programmes, and growing adoption of rapid molecular diagnostic platforms across hospital laboratory networks.

• Regulatory mandates drive mandatory testing requirements.
• Infection prevention programmes sustain testing demand.
• Molecular diagnostic adoption continues expanding.

HAI Testing Demand Trends in Brazil

The Brazil hospital acquired infection testing market is projected to grow at a CAGR of 16.0% through 2036. Growth is shaped by expanding hospital accreditation requirements, increasing infection prevention investment, and growing molecular diagnostic infrastructure availability.

• Accreditation requirements drive institutional testing adoption.
• Infection prevention investment supports laboratory expansion.
• Molecular diagnostic availability is improving.

Mexico HAI Testing Market Growth Outlook

The Mexico hospital acquired infection testing market is projected to grow at a CAGR of 14.7% through 2036. Growth reflects rising healthcare facility standards, growing HAI awareness, and expanding laboratory capacity across hospital and diagnostic centre networks.

• Facility standards drive infection monitoring requirements.
• HAI awareness improves testing adoption.
• Laboratory capacity expansion supports testing volumes.

Argentina HAI Testing Market Demand Analysis

The Argentina hospital acquired infection testing market is projected to grow at a CAGR of 13.4% through 2036. Demand is supported by increasing healthcare quality standards, growing hospital infection surveillance, and expanding access to rapid diagnostic testing technologies.

• Healthcare quality standards support testing demand.
• Infection surveillance requirements drive adoption.
• Rapid diagnostic access is improving.

HAI Testing Market Opportunity in Chile

The Chile hospital acquired infection testing market is projected to grow at a CAGR of 12.2% through 2036. Growth is supported by high healthcare system standards, established hospital infection prevention frameworks, and growing molecular diagnostic platform adoption.

• Healthcare standards support structured testing programmes.
• Infection prevention frameworks drive consistent demand.
• Molecular diagnostic adoption is expanding.

Competitive Benchmarking and Company Positioning

Americas Hospital Acquired Infection Testing Market Analysis By Company

• Thermo Fisher Scientific, bioMerieux, Becton Dickinson, and Abbott hold leading positions through comprehensive diagnostic portfolios, molecular testing platforms, and established hospital laboratory distribution networks across the Americas.
• Danaher, Quidel, BioFire Diagnostics, and Qiagen compete through specialized molecular diagnostic platforms, rapid testing solutions, and growing positions in syndromic panel testing for hospital infection applications.
• Competition is shaped by platform integration, where companies offering multiplex panels with broad pathogen coverage and resistance profiling gain advantage in hospital laboratory procurement. Per-test costs and workflow integration remain critical purchasing factors.
• Strategic priorities include expanding multiplex panel coverage, developing point-of-care rapid diagnostic formats, building antimicrobial stewardship integration capabilities, and strengthening distribution across Latin American hospital networks.

Key Companies in the Americas Hospital Acquired Infection Testing Market

• Thermo Fisher Scientific, bioMerieux SA, Becton Dickinson & Co., Abbott are among the leading players in the americas hospital acquired infection testing market globally.
• Danaher, Quidel Corporation, BioFire Diagnostics, Qiagen hold established positions across specific segments and channels.

Recent Industry Developments

• bioMerieux SA / Diagnostic Platform / Multiplex Panels (2025)
  • bioMerieux continued expanding its syndromic panel testing capabilities for hospital acquired infection applications, with focus on bloodstream and respiratory infection panels that combine pathogen identification with resistance marker detection.
• BioFire Diagnostics / Panel Expansion / Clinical Adoption (2025)
  • BioFire expanded clinical adoption of its multiplex PCR panel platform across hospital laboratories in the Americas, with growing utilization for syndromic testing in bloodstream, gastrointestinal, and respiratory infection applications.
• Becton Dickinson & Co. / Molecular Diagnostics / Market Access (2025)
  • Becton Dickinson advanced its molecular diagnostic platform for infection testing with focus on expanding market access across hospital and reference laboratory networks in both North and Latin American markets.

Leading Companies Shaping the Americas Hospital Acquired Infection Testing Market

• Thermo Fisher Scientific
• bioMerieux SA
• Becton Dickinson & Co.
• Abbott
• Danaher
• Quidel Corporation
• BioFire Diagnostics
• Qiagen

Sources and Research References

• Centers for Disease Control and Prevention (CDC). Healthcare-associated infection surveillance data.
• Pan American Health Organization (PAHO). Hospital infection prevention guidelines for the Americas.
• bioMerieux. Diagnostic platform data and HAI testing product portfolio.
• BioFire Diagnostics. Multiplex panel clinical adoption and market data.
• Society for Healthcare Epidemiology of America (SHEA). HAI prevention guidelines and testing recommendations.
• Primary interviews with diagnostic companies, infection control specialists, laboratory directors, and regulatory agencies.

This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.

Key Questions This Report Addresses

• What is the current and future size of the Americas HAI Testing market?
• How fast is this market expected to grow between 2026 and 2036?
• Which test type is likely to lead by 2026?
• Which product category accounts for highest demand?
• What factors are driving demand?
• How is molecular diagnostics reshaping the market?
• Why is the USA the fastest-growing market?
• How are multiplex panels influencing laboratory procurement?
• Which countries show the fastest growth through 2036?
• Who are the key companies?
• How does Fact.MR validate the forecast?

Americas Hospital Acquired Infection Testing Market Definition

The Americas hospital acquired infection testing market covers molecular diagnostic tests, immunoassay-based tests, microbiology culture tests, rapid diagnostic kits, and associated consumables used to detect healthcare-associated pathogens across hospital, diagnostic laboratory, and research settings in North and Latin America.

Americas Hospital Acquired Infection Testing Market Inclusions

• The scope covers Americas regional market size and forecasts for 2026 to 2036 across test type, product, application, end use, sample type, and country.
• It includes country-level demand analysis based on hospital infection rates, regulatory mandates, infection prevention spending, and diagnostic infrastructure.
• The report includes pricing analysis across molecular, immunoassay, and culture-based testing approaches.
• It covers diagnostic technology trends, regulatory frameworks, market drivers and constraints, and the competitive landscape of leading diagnostics companies.

Americas Hospital Acquired Infection Testing Market Exclusions

• The scope excludes infection testing markets outside the Americas region.
• It excludes community-acquired infection testing and sexually transmitted infection testing not classified as hospital acquired.
• The report excludes infection prevention products such as hand hygiene, surface disinfection, and sterilization products.
• It also excludes antimicrobial drugs and vaccines used in infection treatment and prevention.

Americas Hospital Acquired Infection Testing Market Research Methodology

• The methodology combines secondary research, primary interviews, and forecast modelling.
• It draws on 80+ secondary sources and benchmarks 20+ company diagnostic portfolios.
• Market sizing covers major Americas countries through a demand-side model supported by hospital infection data.
• Key inputs include hospital infection rates, testing mandates, diagnostic platform installations, and per-test utilization data.
• The model cross-checks demand with test kit sales, laboratory procurement data, and infection surveillance reports.
• Primary validation includes 15+ interviews across diagnostic companies, hospital infection control specialists, laboratory directors, and regulatory agencies.
• Final estimates go through infection rate validation, testing volume analysis, and sensitivity testing.